Entropy Neurodynamics targets US$1.9B market

• Entropy Neurodynamics has been granted a South African patent for psilocybin-based fibromyalgia treatments.
• The company's stock reacted positively to the news on the Australian Securities Exchange.
• The newly secured intellectual property extends protection until 2043 to support long-term commercialisation plans.

Entropy Neurodynamics (ASX:ENP) secured a South African patent for psilocybin-based fibromyalgia treatments, targeting a US$1.9 billion market.

This development addresses a chronic pain disorder that affects millions of people globally who have limited treatment options.

The granted patent covers specific clinical protocols, dosing regimens, biomarkers, and manufacturing methods under registration number 2025/01722.

The company stated that the legal exclusivity runs until September 2043 to safeguard its psychedelic medicine platform.

Following the announcement, the Entropy Neurodynamics share price was up at $0.036.

The clinical-stage biotechnology firm focuses on developing proprietary psilocin formulations combined with psychotherapy to treat underserved diseases.

Its primary clinical programme involves an intravenous formulation designed to reduce psychedelic treatment times and control patient experiences.